chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Nausea, Vomiting
Clinical narrative: Booster; one time I fainted; Headaches; extreme sensitivity to cold; continuous nausea; continuous brain fog; continuous extreme fatigue; Some vomiting; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Dec2021 13:00 (Lot number: FI8841) at the age of 70 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Osteoporosis" (unspecified if ongoing); "Known allergies: Penicillin" (unspecified if ongoing); "Known allergies: Sulfa drugs" (unspecified if ongoing), notes: Verbatim: Known allergies: Sulfa drugs; "Known allergies: Walnuts" (unspecified if ongoing), notes: Verbatim: Known allergies: Walnuts; "Known allergies: Bee stings" (unspecified if ongoing), notes: Verbatim: Known allergies: Bee stings; "Known allergies: Insect stings" (unspecified if ongoing); "Known allergies: Dust mites" (unspecified if ongoing), notes: Verbatim: Known allergies: Dust mites; "Known allergies: Pollens" (unspecified if ongoing); "Known allergies: Cats" (unspecified if ongoing), notes: Verbatim: Known allergies: Cats; "Known allergies: Dogs" (unspecified if ongoing), notes: Verbatim: Known allergies: Dogs. Concomitant medication(s) included: VIVELLE-DOT; LOSARTAN; VITAMIN C [ASCORBIC ACID]. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EW0172, Location of injection: Arm Right, Vaccine Administration Time: 12:00 PM), administration date: 06May2021, when the patient was 69 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: ERB131, Location of injection: Arm Left, Vaccine Administration Time: 12:00 PM), administration date: 15Apr2021, when the patient was 69 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (medically significant), outcome "unknown", described as "Booster"; SYNCOPE (medically significant) with onset 18Dec2021 12:45, outcome "recovering", described as "one time I fainted"; HEADACHE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Headaches"; TEMPERATURE INTOLERANCE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "extreme sensitivity to cold"; NAUSEA (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous nausea"; FEELING ABNORMAL (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous brain fog"; FATIGUE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous extreme fatigue"; VOMITING (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Some vomiting". Therapeutic measures were not taken as a result of syncope, headache, temperature intolerance, nausea, feeling abnormal, fatigue, vomiting.
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Immunisation, Nausea
Clinical narrative: Booster; one time I fainted; Headaches; extreme sensitivity to cold; continuous nausea; continuous brain fog; continuous extreme fatigue; Some vomiting; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Dec2021 13:00 (Lot number: FI8841) at the age of 70 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Osteoporosis" (unspecified if ongoing); "Known allergies: Penicillin" (unspecified if ongoing); "Known allergies: Sulfa drugs" (unspecified if ongoing), notes: Verbatim: Known allergies: Sulfa drugs; "Known allergies: Walnuts" (unspecified if ongoing), notes: Verbatim: Known allergies: Walnuts; "Known allergies: Bee stings" (unspecified if ongoing), notes: Verbatim: Known allergies: Bee stings; "Known allergies: Insect stings" (unspecified if ongoing); "Known allergies: Dust mites" (unspecified if ongoing), notes: Verbatim: Known allergies: Dust mites; "Known allergies: Pollens" (unspecified if ongoing); "Known allergies: Cats" (unspecified if ongoing), notes: Verbatim: Known allergies: Cats; "Known allergies: Dogs" (unspecified if ongoing), notes: Verbatim: Known allergies: Dogs. Concomitant medication(s) included: VIVELLE-DOT; LOSARTAN; VITAMIN C [ASCORBIC ACID]. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EW0172, Location of injection: Arm Right, Vaccine Administration Time: 12:00 PM), administration date: 06May2021, when the patient was 69 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: ERB131, Location of injection: Arm Left, Vaccine Administration Time: 12:00 PM), administration date: 15Apr2021, when the patient was 69 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (medically significant), outcome "unknown", described as "Booster"; SYNCOPE (medically significant) with onset 18Dec2021 12:45, outcome "recovering", described as "one time I fainted"; HEADACHE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Headaches"; TEMPERATURE INTOLERANCE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "extreme sensitivity to cold"; NAUSEA (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous nausea"; FEELING ABNORMAL (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous brain fog"; FATIGUE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous extreme fatigue"; VOMITING (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Some vomiting". Therapeutic measures were not taken as a result of syncope, headache, temperature intolerance, nausea, feeling abnormal, fatigue, vomiting.
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Syncope, Temperature intolerance, Vomiting
Clinical narrative: Booster; one time I fainted; Headaches; extreme sensitivity to cold; continuous nausea; continuous brain fog; continuous extreme fatigue; Some vomiting; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Dec2021 13:00 (Lot number: FI8841) at the age of 70 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Osteoporosis" (unspecified if ongoing); "Known allergies: Penicillin" (unspecified if ongoing); "Known allergies: Sulfa drugs" (unspecified if ongoing), notes: Verbatim: Known allergies: Sulfa drugs; "Known allergies: Walnuts" (unspecified if ongoing), notes: Verbatim: Known allergies: Walnuts; "Known allergies: Bee stings" (unspecified if ongoing), notes: Verbatim: Known allergies: Bee stings; "Known allergies: Insect stings" (unspecified if ongoing); "Known allergies: Dust mites" (unspecified if ongoing), notes: Verbatim: Known allergies: Dust mites; "Known allergies: Pollens" (unspecified if ongoing); "Known allergies: Cats" (unspecified if ongoing), notes: Verbatim: Known allergies: Cats; "Known allergies: Dogs" (unspecified if ongoing), notes: Verbatim: Known allergies: Dogs. Concomitant medication(s) included: VIVELLE-DOT; LOSARTAN; VITAMIN C [ASCORBIC ACID]. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EW0172, Location of injection: Arm Right, Vaccine Administration Time: 12:00 PM), administration date: 06May2021, when the patient was 69 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: ERB131, Location of injection: Arm Left, Vaccine Administration Time: 12:00 PM), administration date: 15Apr2021, when the patient was 69 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (medically significant), outcome "unknown", described as "Booster"; SYNCOPE (medically significant) with onset 18Dec2021 12:45, outcome "recovering", described as "one time I fainted"; HEADACHE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Headaches"; TEMPERATURE INTOLERANCE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "extreme sensitivity to cold"; NAUSEA (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous nausea"; FEELING ABNORMAL (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous brain fog"; FATIGUE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous extreme fatigue"; VOMITING (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Some vomiting". Therapeutic measures were not taken as a result of syncope, headache, temperature intolerance, nausea, feeling abnormal, fatigue, vomiting.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: COVID breakthrough case
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: COVID breakthrough case
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Axillary pain, Blister, Chills, Immunisation
Clinical narrative: blister; skin rash; itching; booster dose; fever; arm pain; soreness under armpit; weakness; chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 16Dec2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (Dose 2, MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 16Dec2021, outcome "unknown", described as "booster dose"; BLISTER (non-serious) with onset 17Dec2021, outcome "unknown", described as "blister"; PYREXIA (non-serious) with onset 16Dec2021, outcome "unknown", described as "fever"; PAIN IN EXTREMITY (non-serious) with onset 16Dec2021, outcome "unknown", described as "arm pain"; AXILLARY PAIN (non-serious) with onset 16Dec2021, outcome "unknown", described as "soreness under armpit"; ASTHENIA (non-serious) with onset 16Dec2021, outcome "unknown", described as "weakness"; CHILLS (non-serious) with onset 16Dec2021, outcome "unknown", described as "chills"; RASH (non-serious) with onset 17Dec2021, outcome "unknown", described as "skin rash"; PRURITUS (non-serious) with onset 17Dec2021, outcome "unknown", described as "itching".  Additional information: Got covid vaccine 16Dec2021 - developed right arm pain and soreness and then under armpit pain at same arm site. In addition, extremely weakness, fever and chills. Also got skin rashes developing 24 hours after, itchy blisters on skin.   The lot number for bnt162b2 was not provided and will be requested during follow up.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Rash, Vaccination site pain
Clinical narrative: blister; skin rash; itching; booster dose; fever; arm pain; soreness under armpit; weakness; chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 16Dec2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (Dose 2, MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 16Dec2021, outcome "unknown", described as "booster dose"; BLISTER (non-serious) with onset 17Dec2021, outcome "unknown", described as "blister"; PYREXIA (non-serious) with onset 16Dec2021, outcome "unknown", described as "fever"; PAIN IN EXTREMITY (non-serious) with onset 16Dec2021, outcome "unknown", described as "arm pain"; AXILLARY PAIN (non-serious) with onset 16Dec2021, outcome "unknown", described as "soreness under armpit"; ASTHENIA (non-serious) with onset 16Dec2021, outcome "unknown", described as "weakness"; CHILLS (non-serious) with onset 16Dec2021, outcome "unknown", described as "chills"; RASH (non-serious) with onset 17Dec2021, outcome "unknown", described as "skin rash"; PRURITUS (non-serious) with onset 17Dec2021, outcome "unknown", described as "itching".  Additional information: Got covid vaccine 16Dec2021 - developed right arm pain and soreness and then under armpit pain at same arm site. In addition, extremely weakness, fever and chills. Also got skin rashes developing 24 hours after, itchy blisters on skin.   The lot number for bnt162b2 was not provided and will be requested during follow up.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Pruritus, Pyrexia, Rash
Clinical narrative: blister; skin rash; itching; booster dose; fever; arm pain; soreness under armpit; weakness; chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 16Dec2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (Dose 2, MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 16Dec2021, outcome "unknown", described as "booster dose"; BLISTER (non-serious) with onset 17Dec2021, outcome "unknown", described as "blister"; PYREXIA (non-serious) with onset 16Dec2021, outcome "unknown", described as "fever"; PAIN IN EXTREMITY (non-serious) with onset 16Dec2021, outcome "unknown", described as "arm pain"; AXILLARY PAIN (non-serious) with onset 16Dec2021, outcome "unknown", described as "soreness under armpit"; ASTHENIA (non-serious) with onset 16Dec2021, outcome "unknown", described as "weakness"; CHILLS (non-serious) with onset 16Dec2021, outcome "unknown", described as "chills"; RASH (non-serious) with onset 17Dec2021, outcome "unknown", described as "skin rash"; PRURITUS (non-serious) with onset 17Dec2021, outcome "unknown", described as "itching".  Additional information: Got covid vaccine 16Dec2021 - developed right arm pain and soreness and then under armpit pain at same arm site. In addition, extremely weakness, fever and chills. Also got skin rashes developing 24 hours after, itchy blisters on skin.   The lot number for bnt162b2 was not provided and will be requested during follow up.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Bedridden, Immunisation, Loss of personal independence in daily activities, Robust take following exposure to vaccinia virus
Clinical narrative: symptomatic for the Omicron variant; symptomatic for the Omicron variant; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient of unspecified age received bnt162b2 (BNT162B2), via an unspecified route of administration, administration date Aug2021 (Batch/Lot number: unknown) at an unspecified age as dose 3 (booster), single, via an unspecified route of administration on an unspecified date (Batch/Lot number: unknown) at an unspecified age as dose 2, single and via an unspecified route of administration on an unspecified date (Batch/Lot number: unknown) at an unspecified age as dose 1, single for covid-19 immunization. Relevant medical history included: "immunocompromised" (unspecified if ongoing), notes: due to medication. The patient's concomitant medications were not reported. The following information was reported: IMMUNISATION (medically significant) with onset date Aug2021, outcome "unknown", described as "Booster"; DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "symptomatic for the Omicron variant". Additional information: the patient was calling to ask regarding another booster dose as she already received the first booster dose in Aug2021.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Drug ineffective, Immunisation, Suspected COVID-19
Clinical narrative: symptomatic for the Omicron variant; symptomatic for the Omicron variant; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient of unspecified age received bnt162b2 (BNT162B2), via an unspecified route of administration, administration date Aug2021 (Batch/Lot number: unknown) at an unspecified age as dose 3 (booster), single, via an unspecified route of administration on an unspecified date (Batch/Lot number: unknown) at an unspecified age as dose 2, single and via an unspecified route of administration on an unspecified date (Batch/Lot number: unknown) at an unspecified age as dose 1, single for covid-19 immunization. Relevant medical history included: "immunocompromised" (unspecified if ongoing), notes: due to medication. The patient's concomitant medications were not reported. The following information was reported: IMMUNISATION (medically significant) with onset date Aug2021, outcome "unknown", described as "Booster"; DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "symptomatic for the Omicron variant". Additional information: the patient was calling to ask regarding another booster dose as she already received the first booster dose in Aug2021.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Antiacetylcholine receptor antibody, Autonomic nervous system imbalance, Blood immunoglobulin A normal, Borrelia test negative, CSF cell count normal
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: CSF culture negative, CSF protein increased, Cardiac failure congestive, Cardiomegaly, Chest X-ray abnormal
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Diastolic dysfunction, Echocardiogram abnormal, Ejection fraction normal, Guillain-Barre syndrome, Hypertension
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia, Hyporeflexia, Hypoxia, Immunoglobulin therapy, Klebsiella test positive
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Loss of proprioception, Lumbar puncture abnormal, Magnetic resonance imaging spinal normal, Mechanical ventilation, Muscular weakness
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pneumonitis aspiration, Procalcitonin increased, Sputum culture positive, Tachycardia, Troponin I increased
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Vitamin B12 normal
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Fatigue, Guillain-Barre syndrome
Clinical narrative: fatigue; weakness; positive for Gillian barre; This spontaneous case was reported by a physician and describes the occurrence of FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for Hypertension.    On 29-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (fatigue) (seriousness criterion hospitalization), ASTHENIA (weakness) (seriousness criterion hospitalization) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 6 days due to ASTHENIA, FATIGUE and GUILLAIN-BARRE SYNDROME. The patient was treated with IMMUNOGLOBULIN [IMMUNOGLOBULINS NOS] (intravenous) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (fatigue), ASTHENIA (weakness) and GUILLAIN-BARRE SYNDROME (positive for Gillian barre) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old male patient with medical history of hypertension, who experienced the unexpected, serious events of Fatigue, Asthenia and Guillain-Barre syndrome on an unspecified date after the second dose of mRNA-1273 vaccine. The patient was hospitalized for 6 days. The outcome of the events was unknown. Rechallenge is not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: After 2nd shot on 1-May-2021, I had swollen lymph nodes/armpit for over a week after injection; symptoms started on 2-May-2021. I also experiences chills, fever, fatigue on the day of injection 1-May-2021, which lasted for 2 days.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Axillary pain, COVID-19, Drug ineffective, Fatigue, Inappropriate schedule of product administration
Clinical narrative: After 2nd shot on 1-May-2021, I had swollen lymph nodes/armpit for over a week after injection; symptoms started on 2-May-2021. I also experiences chills, fever, fatigue on the day of injection 1-May-2021, which lasted for 2 days.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Lymph node pain, Pain in extremity, Pyrexia, SARS-CoV-2 test
Clinical narrative: After 2nd shot on 1-May-2021, I had swollen lymph nodes/armpit for over a week after injection; symptoms started on 2-May-2021. I also experiences chills, fever, fatigue on the day of injection 1-May-2021, which lasted for 2 days.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Chills, Fatigue, Lymphadenopathy, Pyrexia
Clinical narrative: After 2nd shot on 1-May-2021, I had swollen lymph nodes/armpit for over a week after injection; symptoms started on 2-May-2021. I also experiences chills, fever, fatigue on the day of injection 1-May-2021, which lasted for 2 days.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood test, Chest X-ray abnormal, Chest discomfort, Chest pain, Chills
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough) and DYSPNOEA (Major breathing issues/Shortness of breath) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045J21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. The patient's past medical history included COVID-19 (Neurological) in November 2020.Concurrent medical conditions included Asthma (asthma attack once a year.) and Wolff-Parkinson-White syndrome (not medicated). On 21-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jan-2022, the patient experienced PULMONARY CALCIFICATION (Calcified nodule of lung). On an unknown date, the patient experienced HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough), DYSPNOEA (Major breathing issues/Shortness of breath), CHEST DISCOMFORT (Chest congestion), LOWER RESPIRATORY TRACT INFECTION (Chest cold for 14 day), PYREXIA (Fever), CHILLS (Hot chills), HEADACHE (Headaches) and FATIGUE (Fatigued). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough), DYSPNOEA (Major breathing issues/Shortness of breath), PULMONARY CALCIFICATION (Calcified nodule of lung), CHEST DISCOMFORT (Chest congestion), PYREXIA (Fever), CHILLS (Hot chills), HEADACHE (Headaches) and FATIGUE (Fatigued) outcome was unknown and LOWER RESPIRATORY TRACT INFECTION (Chest cold for 14 day) had resolved. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available):On 03-Jan-2022, Chest X-ray: abnormal (abnormal) calcified nodule of lung.On 14-Jan-2022, Computerised tomogram: results not reported at 04:30 pm , Results not reported.On an unknown date, Blood test: results not reported Results not reported. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Concomitant medication included inhaler(unspecified). Treatment medications also included nebulizer (5 times a day) and inhaler(not specified.) Patient stated she would be going to a cardiologist and pulmonologist on the day of reporting.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Computerised tomogram, Cough, Dyspnoea, Fatigue, Headache
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough) and DYSPNOEA (Major breathing issues/Shortness of breath) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045J21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. The patient's past medical history included COVID-19 (Neurological) in November 2020.Concurrent medical conditions included Asthma (asthma attack once a year.) and Wolff-Parkinson-White syndrome (not medicated). On 21-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jan-2022, the patient experienced PULMONARY CALCIFICATION (Calcified nodule of lung). On an unknown date, the patient experienced HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough), DYSPNOEA (Major breathing issues/Shortness of breath), CHEST DISCOMFORT (Chest congestion), LOWER RESPIRATORY TRACT INFECTION (Chest cold for 14 day), PYREXIA (Fever), CHILLS (Hot chills), HEADACHE (Headaches) and FATIGUE (Fatigued). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough), DYSPNOEA (Major breathing issues/Shortness of breath), PULMONARY CALCIFICATION (Calcified nodule of lung), CHEST DISCOMFORT (Chest congestion), PYREXIA (Fever), CHILLS (Hot chills), HEADACHE (Headaches) and FATIGUE (Fatigued) outcome was unknown and LOWER RESPIRATORY TRACT INFECTION (Chest cold for 14 day) had resolved. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available):On 03-Jan-2022, Chest X-ray: abnormal (abnormal) calcified nodule of lung.On 14-Jan-2022, Computerised tomogram: results not reported at 04:30 pm , Results not reported.On an unknown date, Blood test: results not reported Results not reported. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Concomitant medication included inhaler(unspecified). Treatment medications also included nebulizer (5 times a day) and inhaler(not specified.) Patient stated she would be going to a cardiologist and pulmonologist on the day of reporting.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hyperhidrosis, Nasopharyngitis, Pulmonary calcification, Pyrexia, Rhinorrhoea
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough) and DYSPNOEA (Major breathing issues/Shortness of breath) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045J21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. The patient's past medical history included COVID-19 (Neurological) in November 2020.Concurrent medical conditions included Asthma (asthma attack once a year.) and Wolff-Parkinson-White syndrome (not medicated). On 21-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jan-2022, the patient experienced PULMONARY CALCIFICATION (Calcified nodule of lung). On an unknown date, the patient experienced HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough), DYSPNOEA (Major breathing issues/Shortness of breath), CHEST DISCOMFORT (Chest congestion), LOWER RESPIRATORY TRACT INFECTION (Chest cold for 14 day), PYREXIA (Fever), CHILLS (Hot chills), HEADACHE (Headaches) and FATIGUE (Fatigued). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (Broke fever in pool of sweat for 4 nights which kept getting worse), HEAD DISCOMFORT (Massive pressure in head), INSOMNIA (Insomnia), COUGH (Developed a cold cough), DYSPNOEA (Major breathing issues/Shortness of breath), PULMONARY CALCIFICATION (Calcified nodule of lung), CHEST DISCOMFORT (Chest congestion), PYREXIA (Fever), CHILLS (Hot chills), HEADACHE (Headaches) and FATIGUE (Fatigued) outcome was unknown and LOWER RESPIRATORY TRACT INFECTION (Chest cold for 14 day) had resolved. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available):On 03-Jan-2022, Chest X-ray: abnormal (abnormal) calcified nodule of lung.On 14-Jan-2022, Computerised tomogram: results not reported at 04:30 pm , Results not reported.On an unknown date, Blood test: results not reported Results not reported. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Concomitant medication included inhaler(unspecified). Treatment medications also included nebulizer (5 times a day) and inhaler(not specified.) Patient stated she would be going to a cardiologist and pulmonologist on the day of reporting.